A hole in one of PAR’s market positions. What impact will the injectable PPS clinical trial program from the University of Western Australia research group have on PAR operations?This is a $3.5M grant to investigate the effectiveness of different routes of administration of injectable PPS- subcutaneous and intra-muscular. (https://research-repository.uwa.edu.au/en/projects/comparative-and-cost-effectiveness-of-different-protocols-of-pent) which is legal. A clear PPS competitor. The Perth group shows significant similarity with PAR protocol. How can this be?How would the Perth competition influence the value of PAR IP? If Capital 51 (next door) had knowledge of the new local Perth group, did this influence their exit from PAR? Is PAR not protected by the patents?Who else is involved or in the know?DYOR
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
0.015(5.36%) |
Mkt cap ! $121.4M | |||
| Open | High | Low | Value | Volume |
| 29.0¢ | 30.3¢ | 28.5¢ | $226.5K | 767.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 114595 | 29.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.5¢ | 21430 | 2 |
View Market Depth
| Last trade - 16.10pm 19/09/2025 (20 minute delay) ? |
| PAR (ASX) Chart |